{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:33:26Z","timestamp":1789544006748,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ejps.2020.105369","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T07:11:42Z","timestamp":1589872302000},"page":"105369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Biomarkers of disease activity and other factors as predictors of adalimumab pharmacokinetics in inflammatory bowel disease"],"prefix":"10.1016","volume":"150","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-3686","authenticated-orcid":false,"given":"Jos\u00e9 Germ\u00e1n","family":"S\u00e1nchez-Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1232-1763","authenticated-orcid":false,"given":"Jon\u00e1s Samuel","family":"P\u00e9rez-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Rebollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Victoria","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2020.105369_bib0001","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2222.2009.03207.x","article-title":"Immunoglobulin G4: an odd antibody","volume":"39","author":"Aalberse","year":"2009","journal-title":"Clin. Exp. Allergy"},{"issue":"2","key":"10.1016\/j.ejps.2020.105369_bib0002","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/ecco-jcc\/jjv190","article-title":"Impact of new treatments on hospitalisation, surgery, infection, and mortality in ibd: a focus paper by the epidemiology committee of ECCO","volume":"10","author":"Annese","year":"2016","journal-title":"J. Crohns. Colitis."},{"key":"10.1016\/j.ejps.2020.105369_bib0003","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cgh.2016.08.015","article-title":"Level of fecal calprotectin correlates with severity of small-bowel Crohn's disease, measured by balloon-assisted endoscopy and computed tomography enterography","volume":"15","author":"Arai","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.ejps.2020.105369_bib0004","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/0004563215604866","article-title":"Serum trough infliximab and anti-infliximab antibodies in a cohort of gastroenterology and rheumatology patients\u2019 infliximab therapeutic drug monitoring","volume":"53","author":"Barlow","year":"2016","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.ejps.2020.105369_bib0005","series-title":"Applied Clinical Pharmacokinetics","first-page":"93","author":"Bauer","year":"2001"},{"key":"10.1016\/j.ejps.2020.105369_bib0006","series-title":"NONMEM 7.1.0 Users Guides","author":"Beal","year":"2009"},{"issue":"2","key":"10.1016\/j.ejps.2020.105369_bib0007","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/FTD.0000000000000494","article-title":"Explaining interpatient variability in adalimumab pharmacokinetics in patients with Crohn's disease","volume":"40","author":"Berends","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2020.105369_bib0008","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2020.105369_bib0009","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jim.2015.01.007","article-title":"Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients","volume":"418","author":"Bloem","year":"2015","journal-title":"J. Immunol. Methods"},{"issue":"3","key":"10.1016\/j.ejps.2020.105369_bib0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MEG.0000000000000544","article-title":"Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels","volume":"28","author":"Bond","year":"2016","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.ejps.2020.105369_bib0011","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2036.2011.04946.x","article-title":"Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients","volume":"35","author":"Bultman","year":"2012","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2020.105369_bib0012","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1097\/MIB.0000000000000404","article-title":"Fecal calprotectin in ileal Crohn\u2019s disease: relationship with magnetic resonance enterography and a pathology score","volume":"21","author":"Cerrillo","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejps.2020.105369_bib0013","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00606431","article-title":"Aminoglycoside dosage adjustment in renal failure: a hand-held calculator program","volume":"22","author":"Chennavasin","year":"1982","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ejps.2020.105369_bib0014","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.ejps.2020.105369_bib0015","first-page":"303","article-title":"A formula to estimate the approximate surface area if height and weight be known. 1916","volume":"5","author":"Du Bois","year":"1989","journal-title":"Nutrition"},{"key":"10.1016\/j.ejps.2020.105369_bib0016","series-title":"Pharmacometrics: The Science of Quantitative Pharmacology","author":"Ette","year":"2007"},{"key":"10.1016\/j.ejps.2020.105369_bib0017","unstructured":"European Medicines Agency (EMA). Humira product information. Avaiable from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/humira. Accessed September 1, 2019."},{"key":"10.1016\/j.ejps.2020.105369_bib0018","unstructured":"Food and Drug Administration (FDA). Adalimumab product approval information. Avaiable from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125057s410lbl.pdf. Accessed September 1, 2019."},{"issue":"1","key":"10.1016\/j.ejps.2020.105369_bib0019","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"Third European evidence-based consensus on the diagnosis and management of Crohn\u2019s Disease 2016: part 1: diagnosis and medical management","volume":"11","author":"Gomollon","year":"2017","journal-title":"J. Crohns. Colitis."},{"issue":"1","key":"10.1016\/j.ejps.2020.105369_bib0020","first-page":"24","article-title":"Persistence of biological agents over an eight-year period in rheumatoid arthritis and spondyloarthritis patients","volume":"43","author":"Gonz\u00e1lez-Fern\u00e1ndez","year":"2019","journal-title":"Farm Hosp."},{"issue":"3","key":"10.1016\/j.ejps.2020.105369_bib0021","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/cei.13112","article-title":"Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab","volume":"192","author":"Gorovits","year":"2018","journal-title":"Clin. Exp. Immunol."},{"issue":"8","key":"10.1016\/j.ejps.2020.105369_bib0022","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.gastrohep.2018.05.029","article-title":"Recommendations of the Spanish working group on Crohn's disease and ulcerative colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease","volume":"41","author":"Guardiola","year":"2018","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejps.2020.105369_bib0023","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/oby.21003","article-title":"Adipose tissue as an immunological organ","volume":"23","author":"Grant","year":"2015","journal-title":"Obesity (Silver Spring)"},{"issue":"8167","key":"10.1016\/j.ejps.2020.105369_bib0024","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's-disease activity","volume":"315","author":"Harvey","year":"1980","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejps.2020.105369_bib0025","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/cei.12955","article-title":"Considerations for dosing immunoglobulin in obese patients","volume":"188","author":"Hodkinson","year":"2017","journal-title":"Clin. Exp. Immunol."},{"issue":"12","key":"10.1016\/j.ejps.2020.105369_bib0026","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/rheumatology\/kew326","article-title":"The influence of obesity on response to tumour necrosis factor-\u03b1 inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries","volume":"55","author":"H\u00f8jgaard","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ejps.2020.105369_bib0027","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3109\/00365521.2011.560680","article-title":"Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon","volume":"46","author":"Jensen","year":"2011","journal-title":"Scand. J. Gastroenterol."},{"issue":"11","key":"10.1016\/j.ejps.2020.105369_bib0028","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1007\/s10620-018-5202-5","article-title":"at alt. Maintenance adalimumab concentrations are associated with biochemical, endoscopic, and histologic remission in inflammatory bowel disease","volume":"63","author":"Juncadella","year":"2018","journal-title":"Dig Dis. Sci."},{"issue":"11","key":"10.1016\/j.ejps.2020.105369_bib0029","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1097\/MIB.0000000000001202","article-title":"Fecal Calprotectin More Accurately Predicts Endoscopic Remission of Crohn's Disease than Serological Biomarkers Evaluated Using Balloon-assisted Enteroscopy","volume":"23","author":"Kawashima","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"issue":"12","key":"10.1016\/j.ejps.2020.105369_bib0030","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejps.2020.105369_bib0031","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/MIB.0000000000000057","article-title":"Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity","volume":"20","author":"Lin","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejps.2020.105369_bib0032","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.crohns.2013.05.005","article-title":"A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease","volume":"7","author":"Lobat\u00f3n","year":"2013","journal-title":"J. Crohns. Colitis."},{"issue":"11\u201312","key":"10.1016\/j.ejps.2020.105369_bib0033","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.14368","article-title":"Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases","volume":"46","author":"Mitrev","year":"2017","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2020.105369_bib0034","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/ajg.2015.120","article-title":"C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis","volume":"110","author":"Mosli","year":"2015","journal-title":"Am. J. Gastroenterol."},{"issue":"33","key":"10.1016\/j.ejps.2020.105369_bib0035","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.3748\/wjg.v24.i33.3681","article-title":"From bench to bedside: fecal calprotectin in inflammatory bowel diseases clinical setting","volume":"24","author":"Mumolo","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.ejps.2020.105369_bib0036","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/psp4.12161","article-title":"Model Evaluation of Continuous Data Pharmacometric Models: metrics and Graphics","volume":"6","author":"Nguyen","year":"2017","journal-title":"CPT Pharmacometr. Syst. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejps.2020.105369_bib0037","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms","volume":"91","author":"Ord\u00e1s","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.ejps.2020.105369_bib0038","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases","volume":"17","author":"Papamichael","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.ejps.2020.105369_bib0039","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/ecco-jcc\/jjz018","article-title":"Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared with standard of care in patients with inflammatory bowel disease","volume":"13","author":"Papamichael","year":"2019","journal-title":"J. Crohns. Colitis."},{"key":"10.1016\/j.ejps.2020.105369_bib0040","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1097\/MIB.0000000000000037","article-title":"Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"20","author":"Paul","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"issue":"3","key":"10.1016\/j.ejps.2020.105369_bib0042","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","article-title":"Mechanistic determinants of biotherapeutics absorption following SC administration","volume":"14","author":"Richter","year":"2012","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.ejps.2020.105369_bib0043","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cgh.2013.07.010","article-title":"Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases","volume":"12","author":"Roblin","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.ejps.2020.105369_bib0044","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0004563218782286","article-title":"Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseases","volume":"56","author":"Sanchez-Hernandez","year":"2019","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.ejps.2020.105369_bib0045","first-page":"1","article-title":"A 3\u2010year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease","author":"S\u00e1nchez\u2010Hern\u00e1ndez","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105369_bib0046","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","article-title":"Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions","volume":"11","author":"Savic","year":"2009","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2020.105369_bib0047","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/MIB.0000000000000327","article-title":"Pharmacokinetics and exposure efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study","volume":"21","author":"Sharma","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"issue":"2","key":"10.1016\/j.ejps.2020.105369_bib0048","doi-asserted-by":"crossref","first-page":"353","DOI":"10.5114\/aoms.2014.43672","article-title":"Is faecal calprotectin equally useful in all Crohn's disease locations? A prospective, comparative study","volume":"11","author":"Stawczyk-Eder","year":"2015","journal-title":"Arch. Med. Sci."},{"issue":"9","key":"10.1016\/j.ejps.2020.105369_bib0049","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00228-015-1892-1","article-title":"Pharmacokinetics of adalimumab in Crohn's disease","volume":"71","author":"Ternant","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejps.2020.105369_bib0050","first-page":"39","article-title":"Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: adding value to current practice","volume":"55","author":"Vande Casteele","year":"2015","journal-title":"J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.ejps.2020.105369_bib0051","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/ecco-jcc\/jjz050","article-title":"Subcutaneous absorption contributes to observed interindividual variability in adalimumab serum concentrations in Crohn's disease: a prospective multicentre study","volume":"13","author":"Vande Casteele","year":"2019","journal-title":"J. Crohns. Colitis."},{"key":"10.1016\/j.ejps.2020.105369_bib0052","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/gutjnl-2016-313071","article-title":"Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial","volume":"67","author":"Van Stappen","year":"2018","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.ejps.2020.105369_bib0053","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.ejps.2020.105369_bib0054","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10928-011-9201-9","article-title":"Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models","volume":"38","author":"Xu","year":"2011","journal-title":"J. Pharmacokinet. Pharmacodyn."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720301585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720301585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:54:15Z","timestamp":1760529255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098720301585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":53,"alternative-id":["S0928098720301585"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105369","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers of disease activity and other factors as predictors of adalimumab pharmacokinetics in inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105369"}}